Creating a vaccine to prevent ear infections in children
Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media
This study is testing a new vaccine called CMTX-301 to help prevent ear infections in kids by breaking down the protective barriers that bacteria use to hide from the immune system, making it easier for the body to fight off these infections.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clarametyx Bioscience, INC. NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10762345 on NIH RePORTER |
What this research studies
This research focuses on developing a vaccine to prevent otitis media, a common bacterial ear infection in children. The vaccine, CMTX-301, targets specific components of bacterial biofilms that protect the bacteria from the immune system. By collapsing these biofilms, the vaccine aims to enhance the body's ability to clear the infection and reduce the incidence of ear infections. This innovative approach addresses the changing landscape of bacteria responsible for these infections, particularly in the wake of existing vaccines.
Who could benefit from this research
Good fit: Ideal candidates for this research are children who frequently suffer from ear infections or are at high risk for developing otitis media.
Not a fit: Patients who do not experience ear infections or have underlying conditions that contraindicate vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the occurrence of ear infections in children, leading to better health outcomes and reduced healthcare costs.
How similar studies have performed: Other research has shown promise in developing vaccines targeting bacterial infections, but this specific approach to otitis media is relatively novel.
Where this research is happening
Columbus, United States
- Clarametyx Bioscience, INC. — Columbus, United States (Active)
Researchers
- Principal investigator: Mcosker, Charles C. — Clarametyx Bioscience, INC.
- Study coordinator: Mcosker, Charles C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.